BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 24212444)

  • 1. Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTATATE.
    Sainz-Esteban A; Baum RP
    Clin Nucl Med; 2013 Dec; 38(12):996-7. PubMed ID: 24212444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance on
    Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
    J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
    Lewis JS; Laforest R; Lewis MR; Anderson CJ
    Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
    Davì MV; Bodei L; Ferdeghini M; Falconi M; Testoni M; Paganelli G; Oliani C; Lo Cascio V; Francia G
    Endocr Pract; 2008 Mar; 14(2):213-8. PubMed ID: 18308661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Case of Metastatic VIPoma With Complete Response to Peptide Radionuclide Receptor Therapy.
    Audil HY; Eiring RA; Kendi AT; Halfdanarson TR
    Pancreas; 2021 Apr; 50(4):e45-e46. PubMed ID: 33939683
    [No Abstract]   [Full Text] [Related]  

  • 9. Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide-secreting tumors.
    Thomason JW; Martin RS; Fincher ME
    Clin Nucl Med; 2000 Sep; 25(9):661-4. PubMed ID: 10983749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
    Makis W; McCann K; Riauka TA; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2016 Jan; 41(1):53-4. PubMed ID: 26562579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy.
    Thisgaard H; Olsen BB; Dam JH; Bollen P; Mollenhauer J; Høilund-Carlsen PF
    J Nucl Med; 2014 Aug; 55(8):1311-6. PubMed ID: 24876207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin.
    Eskens FA; Roelofs EJ; Hermus AR; Verhagen CA
    Anticancer Res; 1997; 17(6D):4667-70. PubMed ID: 9494586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography study on pancreatic somatostatin receptors in normal and diabetic rats with 68Ga-DOTA-octreotide: a potential PET tracer for beta cell mass measurement.
    Sako T; Hasegawa K; Nishimura M; Kanayama Y; Wada Y; Hayashinaka E; Cui Y; Kataoka Y; Senda M; Watanabe Y
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):79-84. PubMed ID: 24220338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
    Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
    Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
    Flückiger A; Schlup P
    Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro release of vasoactive intestinal polypeptide and pancreatic polypeptide from human VIPoma cells and its inhibition by somatostatin analogue (SMS 201-995).
    Yasunami Y; Funakoshi A; Ryu S; Shinozaki H; Jimi A; Miyazaki K; Ikeda S
    Surgery; 1994 Jun; 115(6):713-7. PubMed ID: 8197564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
    Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
    Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.